Free Trial
→ I'm handing you this stock today (From Behind the Markets) (Ad)tc pixel Free MDCXW Stock Alerts

Medicus Pharma (MDCXW) Financials

$0.21 0.00 (0.00%)
As of 11/12/2026 03:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Medicus Pharma

Annual Income Statements for Medicus Pharma

This table shows Medicus Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.31 -11 -47
Consolidated Net Income / (Loss)		 -5.31 -11 -35
Net Income / (Loss) Continuing Operations		 -5.31 -11 -36
Total Pre-Tax Income 		-5.31 -11 -36
Total Operating Income		 -4.73 -11 -34
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 4.73 11 34
Selling, General & Admin Expense		 4.54 7.65 18
Research & Development Expense		 0.19 3.53 16
Total Other Income / (Expense), net		 -0.58 0.05 -1.32
Interest Expense		 - -0.03 0.22
Other Income / (Expense), net		 - 0.03 -1.10
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 -0.00
Basic Earnings per Share		 ($1.53) ($1.16) ($2.74)
Weighted Average Basic Shares Outstanding		 3.48M 9.62M 17.28M
Diluted Earnings per Share		 ($1.53) ($1.16) ($2.74)
Weighted Average Diluted Shares Outstanding		 3.48M 9.62M 17.28M
Weighted Average Basic & Diluted Shares Outstanding		 - 13.41M 39.36M

Quarterly Income Statements for Medicus Pharma

This table shows Medicus Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.71 -3.63 -2.28 -3.54 -5.10 -6.18 -1.67 -34 -9.04 -23
Consolidated Net Income / (Loss)		 -1.71 -3.63 -2.28 -3.54 -5.10 -6.18 -16 -8.18 -9.04 -23
Net Income / (Loss) Continuing Operations		 -1.71 -3.63 -2.28 -3.51 -5.08 -6.14 -1.67 -23 -9.12 -23
Total Pre-Tax Income 		-1.71 -3.63 -2.28 -3.51 -5.08 -6.14 -1.67 -23 -9.12 -23
Total Operating Income		 -1.71 -3.55 -2.33 -3.59 -5.13 -6.02 -0.00 -23 -8.60 -11
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 1.71 3.55 2.33 3.59 5.13 6.02 1.68 22 8.60 23
Selling, General & Admin Expense		 1.39 2.28 1.77 2.22 3.12 4.58 0.00 10 5.89 6.57
Research & Development Expense		 0.32 1.28 0.56 1.37 2.01 1.44 1.68 11 2.70 4.91
Other Operating Expenses / (Income)		 - - - - - - - - - 11
Total Other Income / (Expense), net		 0.00 -0.08 0.06 0.07 0.05 -0.12 0.01 -1.23 -0.52 -0.41
Interest Expense		 - 0.08 -0.06 - 0.00 0.00 -0.01 - 0.37 0.21
Interest & Investment Income		 0.00 - - - 0.02 0.04 - - 0.06 0.00
Other Income / (Expense), net		 - - 0.00 - 0.02 -0.16 - - -0.20 -0.21
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 - 0.00 0.00 - - -0.00 -0.06
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - - - - -0.26
Basic Earnings per Share		 ($0.21) ($0.44) ($0.24) ($0.27) ($0.42) ($0.43) ($1.12) ($0.77) ($0.31) ($0.21)
Weighted Average Basic Shares Outstanding		 8.08M 8.17M 9.51M 9.62M 12.24M 14.28M 18.63M 17.28M 29.54M 55.06M
Diluted Earnings per Share		 ($0.21) ($0.44) ($0.24) ($0.27) ($0.42) ($0.43) ($1.12) ($0.77) ($0.31) ($0.21)
Weighted Average Diluted Shares Outstanding		 8.08M 8.17M 9.51M 9.62M 12.24M 14.28M 18.63M 17.28M 29.54M 55.06M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 13.41M 13.49M 17.82M 22.03M 39.36M 56.66M 63.18M

Annual Cash Flow Statements for Medicus Pharma

This table details how cash moves in and out of Medicus Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.45 2.44 4.54
Net Cash From Operating Activities		 -4.16 -10 -23
Net Cash From Continuing Operating Activities		 -4.16 -10 -23
Net Income / (Loss) Continuing Operations		 -5.31 -11 -35
Consolidated Net Income / (Loss)		 -5.31 -11 -35
Non-Cash Adjustments To Reconcile Net Income		 0.68 0.88 12
Changes in Operating Assets and Liabilities, net		 0.47 0.03 0.57
Net Cash From Investing Activities		 0.00 0.00 -4.62
Net Cash From Continuing Investing Activities		 0.00 0.00 -4.62
Acquisitions		 - 0.00 -4.62
Net Cash From Financing Activities		 5.61 13 32
Net Cash From Continuing Financing Activities		 5.61 13 32
Repayment of Debt		 - 0.00 -7.53
Repurchase of Common Equity		 - 0.00 -0.65
Issuance of Debt		 0.50 5.17 12
Issuance of Common Equity		 0.00 7.52 18
Other Financing Activities, net		 5.11 0.00 10
Effect of Exchange Rate Changes		 - 0.00 -0.00
Cash Interest Paid		 0.00 0.04 0.22

Quarterly Cash Flow Statements for Medicus Pharma

This table details how cash moves in and out of Medicus Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -1.18 7.87 -3.10 -1.14 -0.18 5.69 3.95 -4.91 -2.34 19
Net Cash From Operating Activities		 -1.18 -2.78 -3.10 -3.19 -3.94 -5.47 -6.76 -6.61 -8.97 -6.98
Net Cash From Continuing Operating Activities		 -1.18 -2.78 -3.10 -3.19 -3.94 -5.47 -1.80 -12 -8.97 -6.98
Net Income / (Loss) Continuing Operations		 -1.71 -3.63 -2.28 -3.54 -5.10 -6.18 -16 -8.18 -9.04 -12
Consolidated Net Income / (Loss)		 -1.71 -3.63 -2.28 -3.54 -5.10 -6.18 -16 -8.18 -9.04 -12
Non-Cash Adjustments To Reconcile Net Income		 0.07 0.70 0.03 0.08 0.11 0.48 15 -3.90 1.13 1.91
Changes in Operating Assets and Liabilities, net		 0.46 0.16 -0.85 0.26 1.05 0.23 -1.23 0.52 -1.06 2.79
Net Cash From Financing Activities		 0.00 11 - 2.05 3.76 11 10 6.65 6.83 26
Net Cash From Continuing Financing Activities		 0.00 11 - 2.05 3.76 11 10 6.65 6.83 26
Repayment of Debt		 0.00 - - - -0.03 -0.27 -5.48 -1.75 -3.18 -2.96
Issuance of Common Equity		 0.00 5.47 - 2.05 3.78 6.01 - 8.43 10 6.49
Effect of Exchange Rate Changes		 - - - - - - - - -0.20 0.28
Cash Interest Paid		 - - - - 0.00 - - - 0.10 0.23

Annual Balance Sheets for Medicus Pharma

This table presents Medicus Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.89 5.65 10
Total Current Assets		 1.89 5.38 9.89
Cash & Equivalents		 1.72 4.16 8.71
Prepaid Expenses		 0.17 1.21 1.09
Other Current Assets		 - 0.00 0.10
Plant, Property, & Equipment, net		 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.27 0.17
Other Noncurrent Operating Assets		 0.00 0.27 0.17
Total Liabilities & Shareholders' Equity		 1.89 5.65 10
Total Liabilities		 0.78 2.51 10
Total Current Liabilities		 0.78 2.31 9.94
Short-Term Debt		 - 0.00 5.25
Accounts Payable		 0.21 1.28 3.44
Accrued Expenses		 0.40 0.76 1.00
Other Current Liabilities		 0.17 0.26 0.26
Total Noncurrent Liabilities		 0.00 0.21 0.09
Long-Term Debt		 - 0.00 0.03
Other Noncurrent Operating Liabilities		 0.00 0.21 0.06
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.11 3.13 0.04
Total Preferred & Common Equity		 1.11 3.13 -0.07
Total Common Equity		 1.11 3.13 -0.07
Common Stock		 19 32 64
Retained Earnings		 -18 -29 -64
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.01
Other Equity Adjustments		 - 0.00 0.31
Noncontrolling Interest		 - 0.00 0.10

Quarterly Balance Sheets for Medicus Pharma

This table presents Medicus Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 5.66 12 9.98 7.43 27
Total Current Assets		 5.09 11 9.78 7.28 17
Cash & Equivalents		 3.98 9.67 8.66 6.37 15
Prepaid Expenses		 1.11 1.33 1.12 0.92 1.81
Other Current Assets		 0.00 0.00 0.00 0.00 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.57 0.94 0.20 0.14 10
Other Noncurrent Operating Assets		 0.57 0.94 0.20 0.14 10
Total Liabilities & Shareholders' Equity		 5.66 12 9.98 7.43 27
Total Liabilities		 3.51 8.69 11 6.00 29
Total Current Liabilities		 3.34 8.54 11 5.95 11
Short-Term Debt		 - 4.70 6.79 2.34 3.50
Accounts Payable		 2.04 1.77 2.03 2.28 6.73
Accrued Expenses		 1.06 1.83 1.56 1.04 0.31
Other Current Liabilities		 0.24 0.25 0.28 0.29 0.30
Total Noncurrent Liabilities		 0.17 0.14 0.10 0.05 18
Long-Term Debt		 - - - 0.02 18
Other Noncurrent Operating Liabilities		 0.17 0.14 0.10 0.02 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.15 3.25 -0.80 1.43 -1.72
Total Preferred & Common Equity		 2.15 3.25 6.45 1.33 -1.76
Total Common Equity		 2.15 3.25 6.45 1.33 -1.76
Common Stock		 36 43 6.45 75 83
Retained Earnings		 -34 -40 -0.00 -73 -85
Accumulated Other Comprehensive Income / (Loss)		 - - - -0.19 0.06
Other Equity Adjustments		 - - - 0.31 0.00
Noncontrolling Interest		 - - - 0.10 0.04

Annual Metrics And Ratios for Medicus Pharma

This table displays calculated financial ratios and metrics derived from Medicus Pharma's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 22,029,144.00
DEI Adjusted Shares Outstanding		 0.00 0.00 22,029,144.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -2.15
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -135.85% -217.83%
EBIT Growth		 0.00% -135.85% -217.83%
NOPAT Growth		 0.00% -136.39% -207.30%
Net Income Growth		 0.00% -109.90% -217.73%
EPS Growth		 0.00% 24.18% -136.21%
Operating Cash Flow Growth		 0.00% -146.43% -122.27%
Free Cash Flow Firm Growth		 0.00% 0.00% -192.84%
Invested Capital Growth		 0.00% -69.38% -229.88%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -140.74%
EBIT Q/Q Growth		 0.00% 0.00% -140.74%
NOPAT Q/Q Growth		 0.00% 0.00% -133.30%
Net Income Q/Q Growth		 0.00% 0.00% -15.09%
EPS Q/Q Growth		 0.00% 0.00% -22.32%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -17.65%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% -28.09%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.23% 99.35%
Interest Burden Percent		 112.36% 99.77% 100.63%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -478.18% -525.44% -2,234.82%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -478.18% -525.44% -2,160.94%
Return on Equity Simple (ROE_SIMPLE)		 -478.18% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.31 -7.83 -24
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -116.55% -113.16% -299.89%
Return On Investment Capital (ROIC_SIMPLE)		 -297.90% -249.68% -453.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.73 -11 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.73 -11 -35
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 7.46 0.00
Price to Tangible Book Value (P/TBV)		 0.00 7.46 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 141.28
Long-Term Debt to Equity		 0.00 0.00 0.69
Financial Leverage		 -1.55 -1.39 -2.40
Leverage Ratio		 1.70 1.78 4.95
Compound Leverage Factor		 1.91 1.77 4.98
Debt to Total Capital		 0.00% 0.00% 99.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 98.81%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 1.98%
Common Equity to Total Capital		 100.00% 100.00% -1.27%
Debt to EBITDA		 0.00 0.00 -0.15
Net Debt to EBITDA		 0.00 0.00 0.10
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.22
Net Debt to NOPAT		 0.00 0.00 0.14
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 0.00 -7.45 -19.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 3.31%
Liquidity Ratios		 - - -
Current Ratio		 2.42 2.33 1.00
Quick Ratio		 2.20 1.81 0.88
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -7.40 -22
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -97.51
Operating Cash Flow to Interest Expense		 0.00 0.00 -102.42
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -102.42
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -0.61 -1.03 -3.40
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.42 -2.37
Enterprise Value (EV)		 0.00 19 23
Market Capitalization		 0.00 23 26
Book Value per Share		 $0.32 $0.33 $0.00
Tangible Book Value per Share		 $0.32 $0.33 $0.00
Total Capital		 1.11 3.13 5.31
Total Debt		 0.00 0.00 5.27
Total Long-Term Debt		 0.00 0.00 0.03
Net Debt		 -1.72 -4.16 -3.43
Capital Expenditures (CapEx)		 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.61 -1.09 -3.51
Debt-free Net Working Capital (DFNWC)		 1.11 3.07 5.20
Net Working Capital (NWC)		 1.11 3.07 -0.05
Net Nonoperating Expense (NNE)		 2.00 3.33 11
Net Nonoperating Obligations (NNO)		 -1.72 -4.16 -3.43
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.16) ($2.74)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 9.62M 17.28M
Adjusted Diluted Earnings per Share		 $0.00 ($1.16) ($2.74)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 9.62M 17.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.41M 39.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.31 -7.83 -24
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 -159.43
NOPAT to Interest Expense		 0.00 0.00 -108.15
EBIT Less CapEx to Interest Expense		 0.00 0.00 -159.43
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -108.15
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -1.84%

Quarterly Metrics And Ratios for Medicus Pharma

This table displays calculated financial ratios and metrics derived from Medicus Pharma's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 0.00 0.00 0.00 0.00 13,414,801.00 13,494,861.00 17,816,266.00 22,029,144.00 39,362,109.00 56,658,164.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 13,414,801.00 13,494,861.00 17,816,266.00 22,029,144.00 39,362,109.00 56,658,164.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 -0.38 -0.46 -0.09 -1.56 -0.23 -0.40
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% -198.85% -73.79% 100.00% -547.53% -72.49% -89.19%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% -198.85% -73.79% 100.00% -547.53% -72.49% -89.19%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -200.25% -69.28% 100.00% -547.53% -67.71% -90.80%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -198.85% -70.01% -601.32% -131.43% -77.22% -277.30%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 2.27% -366.67% -185.19% 26.19% 51.16%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -234.85% -96.95% -117.85% -107.08% -127.60% -27.70%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -201.10% -476.47%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -229.88% -40.22% 367.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -108.15% 34.32% -53.60% -42.31% -20.48% 100.00% -154,779,400.00% 62.09% -32.76%
EBIT Q/Q Growth		 0.00% -108.15% 34.32% -53.60% -42.31% -20.48% 100.00% -154,779,400.00% 62.09% -32.76%
NOPAT Q/Q Growth		 0.00% -108.15% 34.32% -53.60% -42.97% -17.36% 100.00% -154,779,400.00% 62.97% -33.52%
Net Income Q/Q Growth		 0.00% -112.78% 37.27% -55.20% -44.28% -21.04% -158.76% 48.79% -10.48% -157.70%
EPS Q/Q Growth		 0.00% -109.52% 45.45% -12.50% -55.56% -2.38% -160.47% 31.25% 59.74% 32.26%
Operating Cash Flow Q/Q Growth		 0.00% -135.93% -11.72% -2.89% -23.48% -38.77% -23.57% 2.20% -35.72% 22.14%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -42.02% 206.48% -623.63% 61.97% -171.91%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -78.21% 6.22% -54.09% -28.09% 24.25% 278.81%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.72% 100.47% 100.65% 955.13% 35.95% 99.15% 99.71%
Interest Burden Percent		 100.00% 102.22% 97.62% 97.93% 99.53% 99.35% 11,154,773.33% 98.06% 103.61% 200.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -525.44% -677.54% -526.17% 3,826.16% -2,234.82% -2,203.04% -7,417.29%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -796.13%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -525.44% -677.54% -526.17% -30,660.32% -2,160.94% -2,140.29% -7,228.97%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.20 -2.49 -1.63 -2.51 -3.59 -4.21 -0.00 -16 -6.02 -8.04
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -24.66% -76.03% -79.07% -1,730.69% 212.35% -75.77% 2,251.80%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -80.07% -167.09% -52.98% 0.00% -306.14% -158.67% -40.63%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.71 -3.55 -2.33 -3.59 -5.10 -6.18 -0.00 -23 -8.80 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.71 -3.55 -2.33 -3.59 -5.10 -6.18 -0.00 -23 -8.80 -12
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 7.46 21.20 13.15 6.69 0.00 10.23 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 7.46 21.20 13.15 6.69 0.00 10.23 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.72
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 1.45 -8.43 141.28 1.66 -12.46
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.69 0.01 -10.43
Financial Leverage		 0.00 0.00 0.00 -1.33 -1.85 -1.53 2.29 -2.40 -2.23 0.89
Leverage Ratio		 0.00 0.00 0.00 1.78 2.63 3.67 -12.40 4.95 3.66 25.63
Compound Leverage Factor		 0.00 0.00 0.00 1.74 2.62 3.65 -1,382,779.60 4.86 3.79 51.26
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 59.13% 113.46% 99.30% 62.35% 108.72%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 59.13% 113.46% 98.81% 61.80% 17.70%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.49% 0.55% 91.02%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.98% 2.69% 0.20%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% 40.87% 107.84% -1.27% 34.96% -8.92%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.28 -0.46 -0.15 -0.06 -0.48
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.29 0.13 0.10 0.10 -0.14
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.40
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.39 -0.66 -0.22 -0.09 -0.71
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.42 0.18 0.14 0.15 -0.21
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.59
Altman Z-Score		 0.00 0.00 0.00 -3.03 -3.24 -3.22 2.29 -14.99 -16.17 -5.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 901.33% 3.31% 2.85% 2.54%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 2.33 1.53 1.29 0.92 1.00 1.22 1.57
Quick Ratio		 0.00 0.00 0.00 1.81 1.19 1.13 0.81 0.88 1.07 1.40
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 -1.75 -2.49 2.65 -14 -5.28 -14
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -14.09 -69.81
Operating Cash Flow to Interest Expense		 0.00 -35.14 0.00 0.00 0.00 0.00 0.00 0.00 -23.94 -33.96
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -35.14 0.00 0.00 0.00 0.00 0.00 0.00 -23.94 -33.96
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -1.03 -1.83 -1.72 -2.65 -3.40 -2.57 4.60
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 -1.83 -1.72 -2.65 -2.37 -0.74 6.32
Enterprise Value (EV)		 0.00 0.00 0.00 19 42 38 41 23 9.66 31
Market Capitalization		 32 27 33 23 46 43 43 26 14 25
Book Value per Share		 $0.00 $0.00 $0.00 $0.33 $0.16 $0.24 $0.36 $0.00 $0.03 ($0.03)
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $0.33 $0.16 $0.24 $0.36 $0.00 $0.03 ($0.03)
Total Capital		 0.00 0.00 0.00 3.13 2.15 7.95 5.98 5.31 3.79 20
Total Debt		 0.00 0.00 0.00 0.00 0.00 4.70 6.79 5.27 2.36 21
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.02 18
Net Debt		 0.00 0.00 0.00 -4.16 -3.98 -4.97 -1.88 -3.43 -4.00 6.33
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -1.09 -2.23 -2.52 -2.75 -3.51 -2.69 -5.53
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 3.07 1.75 7.15 5.91 5.20 3.67 9.64
Net Working Capital (NWC)		 0.00 0.00 0.00 3.07 1.75 2.45 -0.88 -0.05 1.33 6.14
Net Nonoperating Expense (NNE)		 0.51 1.15 0.64 1.03 1.51 1.96 16 -8.07 3.02 15
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -4.16 -3.98 -4.97 -1.85 -3.43 -4.00 6.33
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.27) ($0.42) ($0.43) ($1.12) ($0.77) ($0.31) ($0.21)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 9.62M 12.24M 14.28M 18.63M 17.28M 29.54M 55.06M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.27) ($0.42) ($0.43) ($1.12) ($0.77) ($0.31) ($0.21)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 9.62M 12.24M 14.28M 18.63M 17.28M 29.54M 55.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 13.41M 13.49M 17.82M 22.03M 39.36M 56.66M 63.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.20 -2.49 -1.63 -2.51 -3.59 -4.21 -0.00 -16 -6.02 -8.04
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 -44.97 0.00 0.00 0.00 0.00 0.00 0.00 -23.49 -56.82
NOPAT to Interest Expense		 0.00 -31.48 0.00 0.00 0.00 0.00 0.00 0.00 -16.06 -39.07
EBIT Less CapEx to Interest Expense		 0.00 -44.97 0.00 0.00 0.00 0.00 0.00 0.00 -23.49 -56.82
NOPAT Less CapEx to Interest Expense		 0.00 -31.48 0.00 0.00 0.00 0.00 0.00 0.00 -16.06 -39.07
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.84% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Medicus Pharma (NASDAQ:MDCX) remains an early-stage company with no reported revenue in any of the disclosed quarters. Financial performance continues to be driven by operating expenses, financing activity and changes in debt rather than sales growth.

  • Cash position improved materially in Q2 2026. Cash and equivalents rose to $15.2 million from $6.4 million in Q1 2026 and $9.7 million in Q2 2025. Total current assets also increased to $17.0 million from $7.3 million in the prior quarter.
  • Operating cash burn improved sequentially. Net cash used in operating activities declined to $7.0 million in Q2 2026 from $9.0 million in Q1 2026, although the company continued to consume cash from operations.
  • Liquidity metrics improved from the prior quarter. Current assets exceeded current liabilities by approximately $6.1 million at June 30, 2026, producing a current ratio of roughly 1.6 versus approximately 1.2 at March 31, 2026.
  • Research and development spending reflects continued investment. R&D expense increased from $321,000 in Q1 2024 to $4.9 million in Q2 2026, which may support future product development if the company can eventually commercialize its pipeline.
  • Financing has been the primary source of liquidity. Medicus generated $25.5 million from financing activities in Q2 2026, including $6.5 million from common-equity issuance and debt-related activity. This provided cash to fund operations, but the filing data does not identify the entire financing inflow.
  • The company appears to remain in a pre-revenue development phase. Reported revenue and gross profit were both zero in each supplied 2025 and 2026 income statement, while earlier 2024 quarters also showed no revenue. Investors should focus on commercialization milestones rather than conventional sales-growth metrics.
  • Net losses have widened substantially. Net loss attributable to common shareholders was $22.9 million in Q2 2026, compared with $9.0 million in Q1 2026 and $6.2 million in Q2 2025. Basic loss per share was $0.21 in Q2 2026, versus $0.31 in Q1 2026 and $0.43 in Q2 2025.
  • Operating expenses are accelerating. Total operating expenses increased to $23.0 million in Q2 2026 from $8.6 million in Q1 2026 and $6.0 million in Q2 2025. Selling, general and administrative expense reached $6.6 million, while other operating expenses added $11.5 million.
  • Debt increased sharply during 2026. Total debt rose to approximately $21.5 million at June 30, 2026, including $3.5 million of short-term debt and $18.0 million of long-term debt. At March 31, 2026, total reported debt was approximately $2.4 million.
  • Shareholders’ equity turned negative. Total equity and noncontrolling interests declined from positive $1.4 million in Q1 2026 to negative $1.7 million in Q2 2026. Retained earnings were negative $85.0 million, indicating substantial cumulative losses and increasing balance-sheet risk.

Overall, the latest quarter showed better cash liquidity and a lower operating cash burn than Q1 2026, but those improvements were supported primarily by financing rather than internally generated cash. With zero revenue, recurring operating losses, rising debt, negative equity and continued equity issuance, Medicus Pharma remains highly dependent on obtaining additional capital while advancing its products toward commercialization.

11/13/26 12:22 PM ETAI Generated. May Contain Errors.

Medicus Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Medicus Pharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Medicus Pharma's net income appears to be on a downward trend, with a most recent value of -$35.44 million in 2025, falling from -$5.31 million in 2023. The previous period was -$11.16 million in 2024.

Medicus Pharma's total operating income in 2025 was -$34.36 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $34.36 million

Over the last 2 years, Medicus Pharma's total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

In the past 5 quarters, Medicus Pharma's cash and equivalents has ranged from $3.98 million in Q1 2025 to $15.17 million in Q2 2026, and is currently $15.17 million as of their latest financial filing in Q2 2026.

Medicus Pharma had total debt of $5.27 million at the end of 2025, compared with none in 2024, and none in 2023.

Over the last 2 years, Medicus Pharma's book value per share changed from 0.32 in 2023 to 0.00 in 2025.


Related Companies

Financial statements for NASDAQ:MDCXW last updated on 8/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...
Crypto 101 Media | Sponsoredtc pixel